Literature DB >> 35101336

Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC).

Peter Horak1, Malachi Griffith2, Arpad M Danos2, Beth A Pitel3, Subha Madhavan4, Xuelu Liu5, Cynthia Chow6, Heather Williams7, Leigh Carmody8, Lisa Barrow-Laing9, Damian Rieke10, Simon Kreutzfeldt11, Albrecht Stenzinger12, David Tamborero13, Manuela Benary10, Padma Sheila Rajagopal14, Cristiane M Ida3, Harry Lesmana15, Laveniya Satgunaseelan16, Jason D Merker17, Michael Y Tolstorukov5, Paulo Vidal Campregher18, Jeremy L Warner19, Shruti Rao4, Maya Natesan2, Haolin Shen2, Jeffrey Venstrom20, Somak Roy21, Kayoko Tao22, Rashmi Kanagal-Shamanna23, Xinjie Xu3, Deborah I Ritter24, Kym Pagel25, Kilannin Krysiak2, Adrian Dubuc26, Yassmine M Akkari27, Xuan Shirley Li28, Jennifer Lee29, Ian King30, Gordana Raca31, Alex H Wagner32, Marylin M Li33, Sharon E Plon24, Shashikant Kulkarni24, Obi L Griffith2, Debyani Chakravarty34, Dmitriy Sonkin35.   

Abstract

PURPOSE: Several professional societies have published guidelines for the clinical interpretation of somatic variants, which specifically address diagnostic, prognostic, and therapeutic implications. Although these guidelines for the clinical interpretation of variants include data types that may be used to determine the oncogenicity of a variant (eg, population frequency, functional, and in silico data or somatic frequency), they do not provide a direct, systematic, and comprehensive set of standards and rules to classify the oncogenicity of a somatic variant. This insufficient guidance leads to inconsistent classification of rare somatic variants in cancer, generates variability in their clinical interpretation, and, importantly, affects patient care. Therefore, it is essential to address this unmet need.
METHODS: Clinical Genome Resource (ClinGen) Somatic Cancer Clinical Domain Working Group and ClinGen Germline/Somatic Variant Subcommittee, the Cancer Genomics Consortium, and the Variant Interpretation for Cancer Consortium used a consensus approach to develop a standard operating procedure (SOP) for the classification of oncogenicity of somatic variants.
RESULTS: This comprehensive SOP has been developed to improve consistency in somatic variant classification and has been validated on 94 somatic variants in 10 common cancer-related genes.
CONCLUSION: The comprehensive SOP is now available for classification of oncogenicity of somatic variants.
Copyright © 2022. Published by Elsevier Inc.

Entities:  

Keywords:  Cancer genetic testing; Oncogenicity; Pathogenicity; Somatic variant; Variant classification

Mesh:

Year:  2022        PMID: 35101336      PMCID: PMC9081216          DOI: 10.1016/j.gim.2022.01.001

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.864


  41 in total

1.  PROVEAN web server: a tool to predict the functional effect of amino acid substitutions and indels.

Authors:  Yongwook Choi; Agnes P Chan
Journal:  Bioinformatics       Date:  2015-04-06       Impact factor: 6.937

2.  PHAST and RPHAST: phylogenetic analysis with space/time models.

Authors:  Melissa J Hubisz; Katherine S Pollard; Adam Siepel
Journal:  Brief Bioinform       Date:  2010-12-21       Impact factor: 11.622

3.  TERT promoter mutations in familial and sporadic melanoma.

Authors:  Susanne Horn; Adina Figl; P Sivaramakrishna Rachakonda; Christine Fischer; Antje Sucker; Andreas Gast; Stephanie Kadel; Iris Moll; Eduardo Nagore; Kari Hemminki; Dirk Schadendorf; Rajiv Kumar
Journal:  Science       Date:  2013-01-24       Impact factor: 47.728

4.  Highly recurrent TERT promoter mutations in human melanoma.

Authors:  Franklin W Huang; Eran Hodis; Mary Jue Xu; Gregory V Kryukov; Lynda Chin; Levi A Garraway
Journal:  Science       Date:  2013-01-24       Impact factor: 47.728

5.  Predicting Splicing from Primary Sequence with Deep Learning.

Authors:  Kishore Jaganathan; Sofia Kyriazopoulou Panagiotopoulou; Jeremy F McRae; Siavash Fazel Darbandi; David Knowles; Yang I Li; Jack A Kosmicki; Juan Arbelaez; Wenwu Cui; Grace B Schwartz; Eric D Chow; Efstathios Kanterakis; Hong Gao; Amirali Kia; Serafim Batzoglou; Stephan J Sanders; Kyle Kai-How Farh
Journal:  Cell       Date:  2019-01-17       Impact factor: 41.582

6.  MutSpliceDB: A database of splice sites variants with RNA-seq based evidence on effects on splicing.

Authors:  Alida Palmisano; Suleyman Vural; Yingdong Zhao; Dmitriy Sonkin
Journal:  Hum Mutat       Date:  2021-03-01       Impact factor: 4.878

7.  Evaluation of in silico algorithms for use with ACMG/AMP clinical variant interpretation guidelines.

Authors:  Rajarshi Ghosh; Ninad Oak; Sharon E Plon
Journal:  Genome Biol       Date:  2017-11-28       Impact factor: 13.583

8.  CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer.

Authors:  Malachi Griffith; Nicholas C Spies; Kilannin Krysiak; Joshua F McMichael; Adam C Coffman; Arpad M Danos; Benjamin J Ainscough; Cody A Ramirez; Damian T Rieke; Lynzey Kujan; Erica K Barnell; Alex H Wagner; Zachary L Skidmore; Amber Wollam; Connor J Liu; Martin R Jones; Rachel L Bilski; Robert Lesurf; Yan-Yang Feng; Nakul M Shah; Melika Bonakdar; Lee Trani; Matthew Matlock; Avinash Ramu; Katie M Campbell; Gregory C Spies; Aaron P Graubert; Karthik Gangavarapu; James M Eldred; David E Larson; Jason R Walker; Benjamin M Good; Chunlei Wu; Andrew I Su; Rodrigo Dienstmann; Adam A Margolin; David Tamborero; Nuria Lopez-Bigas; Steven J M Jones; Ron Bose; David H Spencer; Lukas D Wartman; Richard K Wilson; Elaine R Mardis; Obi L Griffith
Journal:  Nat Genet       Date:  2017-01-31       Impact factor: 38.330

9.  Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.

Authors:  Alexander E Perl; Giovanni Martinelli; Jorge E Cortes; Andreas Neubauer; Ellin Berman; Stefania Paolini; Pau Montesinos; Maria R Baer; Richard A Larson; Celalettin Ustun; Francesco Fabbiano; Harry P Erba; Antonio Di Stasi; Robert Stuart; Rebecca Olin; Margaret Kasner; Fabio Ciceri; Wen-Chien Chou; Nikolai Podoltsev; Christian Recher; Hisayuki Yokoyama; Naoko Hosono; Sung-Soo Yoon; Je-Hwan Lee; Timothy Pardee; Amir T Fathi; Chaofeng Liu; Nahla Hasabou; Xuan Liu; Erkut Bahceci; Mark J Levis
Journal:  N Engl J Med       Date:  2019-10-31       Impact factor: 91.245

10.  Recommendations for application of the functional evidence PS3/BS3 criterion using the ACMG/AMP sequence variant interpretation framework.

Authors:  Sarah E Brnich; Ahmad N Abou Tayoun; Fergus J Couch; Garry R Cutting; Marc S Greenblatt; Christopher D Heinen; Dona M Kanavy; Xi Luo; Shannon M McNulty; Lea M Starita; Sean V Tavtigian; Matt W Wright; Steven M Harrison; Leslie G Biesecker; Jonathan S Berg
Journal:  Genome Med       Date:  2019-12-31       Impact factor: 11.117

View more
  3 in total

Review 1.  Daily Practice Assessment of KRAS Status in NSCLC Patients: A New Challenge for the Thoracic Pathologist Is Right around the Corner.

Authors:  Christophe Bontoux; Véronique Hofman; Patrick Brest; Marius Ilié; Baharia Mograbi; Paul Hofman
Journal:  Cancers (Basel)       Date:  2022-03-23       Impact factor: 6.639

2.  Characterization of MET Exon 14 Skipping Alterations (in NSCLC) and Identification of Potential Therapeutic Targets Using Whole Transcriptome Sequencing.

Authors:  So Yeon Kim; Jun Yin; Stephen Bohlman; Phillip Walker; Sanja Dacic; Chul Kim; Hina Khan; Stephen V Liu; Patrick C Ma; Misako Nagasaka; Karen L Reckamp; Jim Abraham; Dipesh Uprety; Feng Wang; Joanne Xiu; Jian Zhang; Haiying Cheng; Balazs Halmos
Journal:  JTO Clin Res Rep       Date:  2022-07-22

3.  Circulating Tumor DNA Profiling of a Diffuse Large B Cell Lymphoma Patient with Secondary Acute Myeloid Leukemia.

Authors:  Irina A Kerle; Ludwig Jägerhuber; Ramona Secci; Nicole Pfarr; Philipp Blüm; Romina Roesch; Katharina S Götze; Wilko Weichert; Florian Bassermann; Jürgen Ruland; Christof Winter
Journal:  Cancers (Basel)       Date:  2022-03-08       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.